Glutamate-Promoted Survival in Hippocampal Neurons: A Defect in Mouse Trisomy 16

  • Linda L. Bambrick
  • Paul J. Yarowsky
  • Bruce K. Krueger
Part of the GWUMC Department of Biochemistry and Molecular Biology Annual Spring Symposia book series (GWUN)

Abstract

Micromolar concentrations of glutamate, acting at non-NMDA, kainate-preferring receptors, increased the survival of cultured mouse hippocampal neurons maintained in serum-free, chemically-defined medium. Glutamate in excess of 20 μM was excitotoxic. Thus, the survival versus glutamate dose response relation was bell-shaped with an optimal glutamate concentration near 1 μM. Hippocampal neurons from mice with the genetic defect, trisomy 16 (Ts16), died 2–3 times faster than normal (euploid) neurons. Moreover, glutamate, at all concentrations tested, failed to increase survival of Ts16 neurons. Ts16 is a naturally-occurring mouse genetic abnormality, the human analog of which (Down syndrome) leads to altered brain development and Alzheimer’s disease. These results demonstrate that the Ts16 genotype confers a defect in the glutamate-mediated survival response of hippocampal neurons and that this defect can account for their accelerated death.

Keywords

Down Syndrome Hippocampal Neuron Basal Forebrain Cerebellar Granule Cell Basal Forebrain Cholinergic Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M.C. Raff, B.A. Barres, J.F. Burne, H.S. Coles, Y. Ishizaki, and M.D. Jacobson, Programmed cell death and the control of cell survival: Lessons from the nervous system. Science 269:695–700 (1993).CrossRefGoogle Scholar
  2. 2.
    H. Potter, Review and hypothesis: Alzheimer disease and Down syndrome — chromosome 21 nondisjunction may underlie both disorders. Am. J. Hum. Genet. 48:1192–1200 (1991).PubMedGoogle Scholar
  3. 3.
    D.M.A. Mann, Down’s syndrome and Alzheimer’s disease: Towards an understanding of the pathogenesis. in “Neurodegeneration”, A.J. Hunter and M. Clark, eds. Academic Press, San Diego, CA (1992).Google Scholar
  4. 4.
    J.T. Coyle, M.L. Oster-Granite, R.H. Reeves, and J.D. Gearhart, Down syndrome, Alzheimer’s disease and the trisomy 16 mouse. Trends Neurosci. 11:390–394 (1988).PubMedCrossRefGoogle Scholar
  5. 5.
    P. Gregor, R.H. Reeves, E.W. Jabs, X. Yang, W. Dackowski, J.M. Rochelle, R.H. Brown, Jr., J.L. Haines, B.F. O’Hara, G.R. Uhl, and M.F. Seldin, Chromosomal localization of glutamate receptor genes: relationship to familial amyotrophic lateral sclerosis and other neurological disorders of mice and humans. Proc. Natl Acad. Sci USA 90:3053–3057 (1993).PubMedCrossRefGoogle Scholar
  6. 6.
    H.S. Singer, M. Tiemeyer, J.C. Hedreen, J. Gearhart, and J.T. Coyle, Morphologic and neurochemical studies of embryonic brain development in murine trisomy 16. Dev. Brain Res. 15:155–166 (1984).CrossRefGoogle Scholar
  7. 7.
    J.D. Gearhart, M.L. Oster-Granite, R.H. Reeves, and J.T. Coyle, Developmental consequences of autosomal aneuploidy in mammals. Dev. Genet. 8:249–265 (1987).PubMedCrossRefGoogle Scholar
  8. 8.
    J. Kiss, M. Schlumpf, and R. Balazs, Selective retardation of the development of the basal forebrain cholinergic and pontine catecholaminergic nuclei in the brain of trisomy 16 mouse, an animal model of Down’s syndrome. Dev. Brain Res. 50:251–264 (1989).CrossRefGoogle Scholar
  9. 9.
    J.E. Sweeney, C.F. Hohmann, M.L. Oster-Granite, and J.T. Coyle, Neurogenesis of the basal forebrain in euploid and trisomy 16 mice: an animal model for developmental disorders in Down syndrome. Neuroscience 31:413–425 (1989).PubMedCrossRefGoogle Scholar
  10. 10.
    M.L. Oster-Granite, The trisomy 16 mouse as an animal model relevant to studies of growth retardation in Down’s syndrome, in “Growth Hormone Treatment in Down’s Syndrome”, S. Castells and K.E. Wisniewski, eds. John Wiley and Sons Ltd, New York (1993).Google Scholar
  11. 11.
    P. Corsi and J.T. Coyle, Nerve growth factor corrects developmental impairments of basal forebrain cholinergic neurons in the trisomy 16 mouse. Proc. Natl Acad. Sci USA 88:1793–1797 (1991).PubMedCrossRefGoogle Scholar
  12. 12.
    D.M. Holtzman, Y. Li, S.J. DeArmond, M.P. McKinley, F.H. Gage, C.J. Epstein, and W.C. Mobley, Mouse model of neurodegeneration: atrophy of basal forebrain cholinergic neurons in trisomy 16 transplants. Proc. Natl Acad. Sci USA 89:1383–1387 (1992).PubMedCrossRefGoogle Scholar
  13. 13.
    G.J. Brewer, J.R. Torricelli, E.K. Evege, and P.J. Price, Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J. Neurosci Res. 35:567–576 (1993).PubMedCrossRefGoogle Scholar
  14. 14.
    K. Unsicker, H. Reichert-Preibsch, R. Schmidt, B. Pettmann, G. Labourdette, and M. Sensenbrenner, Astroglial and fibroblast growth factors have neurotrophic functions for cultured peripheral and central nervous system neurons. Proc. Natl Acad. Sci USA 84:5459–5463 (1987).PubMedCrossRefGoogle Scholar
  15. 15.
    D.W. Choi, Excitotoxic cell death. J. Neurobiol. 23:1261–1276 (1992).PubMedCrossRefGoogle Scholar
  16. 16.
    R. Balazs, O.S. Jorgensen, and N. Hack, N-Methyl-D-aspartate promotes the survival of cerebellar granule cells in culture. Neuroscience 27:437–451 (1988).PubMedCrossRefGoogle Scholar
  17. 17.
    R.D. Burgoyne, M.E. Graham, and M. Cambray-Deakin, Neurotrophic effects of NMDA receptor activation on developing cerebellar granule cells. J. Neurocyt. 22:689–695 (1993).CrossRefGoogle Scholar
  18. 18.
    G.-M. Yan, B. Ni, M. Weller, K.A. Wood, and S.M. Paul, Depolarization or glutamate receptor activation blocks apoptotic cell death of cultured cerebellar granule neurons. Brain Res. 656:43–51 (1994).PubMedCrossRefGoogle Scholar
  19. 19.
    E. Gould, H.A. Cameron, and B.S. McEwen, Blockade of NMDA receptors increases cell death and birth in the developing rat dentate gyrus. J. Comp. Ncurol. 340:551–565 (1994).CrossRefGoogle Scholar
  20. 20.
    H.T.J. Mount, C.F. Dreyfus, and I.B. Black, Purkinje cell survival is differentially regulated by metabotropic and ionotropic excitatory amino acid receptors. J. Neurosci. 13:3173–3179 (1993).PubMedGoogle Scholar
  21. 21.
    A. Copani, V.M.G. Bruno, V. Barresi, G. Battaglia, D.F. Condorelli, and F. Nicoletti, Activation of metabotropic glutamate receptors prevents neuronal apoptosis in culture. J. Neurosci. 64:101–108 (1995).Google Scholar
  22. 22.
    A. Lehman, H. Isacsson, and A. Hamberger, Effects of in vivo administration of kainic acid on the extracellular amino acid pool in the rabbit hippocampus. J. Neurochem. 40:1314–1320 (1983).CrossRefGoogle Scholar
  23. 23.
    K. Sugiyama, A. Brunori, and M.L. Mayer, Glial uptake of excitatory amino acids influences neuronal survival in cultures of mouse hippocampus. Neuroscience 32:779–791 (1989).PubMedCrossRefGoogle Scholar
  24. 24.
    M.P. Mattson and B. Rychlik, Glia protect hippocampal neurons against excitatory amino acid-induced degeneration: involvement of fibroblast growth factor. Int. J. Devl. Neurosci 8:399–415 (1990).CrossRefGoogle Scholar
  25. 25.
    J.D. Rothstein, L. Jin, M. Dykes-Hoberg, and R.W. Kuncl, Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl Acad. Sci USA 90:6591–6595 (1993).PubMedCrossRefGoogle Scholar
  26. 26.
    V. Parpura, T.A. Basarsky, F. Liu, K. Jeftinija, S. Jeftinija, and P.G. Haydon, Glutamate-mediated astrocyte-neuron signalling. Nature 369:744–747 (1994).PubMedCrossRefGoogle Scholar
  27. 27.
    G. Pepeu, L. Ballerini, and A.M. Pugliese, Neurotrophic factors in the aging brain: a review. Arch. Gerontol Geriatr. Suppl. 2:151–158 (1991).Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Linda L. Bambrick
    • 1
  • Paul J. Yarowsky
    • 2
  • Bruce K. Krueger
    • 1
  1. 1.Department of PhysiologyUniversity of Maryland School of MedicineBaltimoreUSA
  2. 2.Department of PharmacologyUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations